Mucipoly AB: Advanced Dual-Action Therapy for Obstructive Airway Diseases
Cafoli Lifecare: Commitment to Respiratory Excellence
Mucipoly AB Tablet represents Cafoli Lifecare's dedication to providing superior therapeutic solutions for prevalent respiratory morbidity. As a leading manufacturer of high-quality pharmaceuticals in India, we ensure that Mucipoly AB meets stringent international standards, positioning it as a trusted treatment for managing chronic obstructive airway conditions.
Scientific Formulation: Acebrophylline 100mg + Acetylcysteine 600mg
Mucipoly AB delivers a powerful, synergistic mechanism of action through its dual-component profile:
-
Acebrophylline (100mg): Acts as a highly effective bronchodilator by inhibiting phosphodiesterase, reducing airway resistance. Simultaneously, it exerts mucoregulatory properties, decreasing mucus viscosity and stimulating ciliary activity.
-
Acetylcysteine (600mg): Functions as a potent direct-acting mucolytic. It breaks down the disulfide bonds in mucus glycoprotein complexes, rapidly thinning bronchial secretions and facilitating easier expectoration.
This fixed-dose combination ensures comprehensive management by simultaneously addressing bronchospasm, mucus hypersecretion, and muco-ciliary clearance, leading to significant improvement in FEV1 and patient quality of life in conditions such as COPD, Chronic Bronchitis, and Asthma.
Quality Assurance and Supply Chain Confidence
Cafoli Lifecare maintains rigorous quality control. Mucipoly AB Tablet is manufactured exclusively in WHO-GMP certified facilities, guaranteeing batch-to-batch consistency, uncompromising safety, and precise therapeutic efficacy.
For Institutions and Trade Partners:
| Feature |
Detail |
| Product Rate |
₹360/- per box (10x15 strips) |
| Supply Capability |
Guaranteed Wholesale and Bulk Supply capacity for institutional and hospital orders. |
| Logistics |
Efficient drug distribution network across India ensures reliable product availability. |
Click Here to know more about Cafoli Lifecare.